$ETST The new MSN-2 medical device has the potential to decrease the spread of HIV by reducing the prevalence of chlamydia in young women. It is fact that when a woman is infected with chlamydia, her risk of contracting HIV is five times the risk of a woman who does not have chlamydia. In addition, chlamydia is the main cause of female infertility in industrialized countries. An undiagnosed, asymptomatic chlamydia infection spreads through the reproductive organs and causes irreversible damage to the woman, requiring specialized care including hospitalization and the administration of intravenous antibiotics, and may have serious effects on any unborn child she is carrying.
Announced on early August, the branding exercise for the MSN-2 device is currently being conducted by Absolu Agency and will be completed in November 2017. ETST is confident that the device will be market-ready as early as Q1 2018. The company’s existing manufacturing facility will be completely reorganized toward the end of November after which will be able to produce up to 10,000 MSN-2 units a week, a production rate that can be increased as needed to meet demand.
Nickolas S. Tabraue, ETST's President, Director, & COO ends with, “We currently have all our partners - Canadian, American, and world-wide looking forward to the launch of the new MSN-2 device for women. Thanks to Dr. Aube’s amazing work we plan on delivering the first sample kits before year-end and plan on sharing updates as they progress as well as many other exciting updates on our patents, KannaBidioiD subsidiary, distribution, education strategy, and expansion.”
